Last reviewed · How we verify

Applied Biology, Inc. — Portfolio Competitive Intelligence Brief

Applied Biology, Inc. pipeline: 0 marketed, 0 filed, 3 Phase 3, 1 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 3 Phase 3 1 Phase 2 6 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
CS-001 CS-001 phase 3 SGLT2 inhibitor SGLT2 Diabetes
DA-002 DA-002 phase 3 SGLT2 inhibitor SGLT2 Diabetes
DA-007 DA-007 phase 3 SGLT2 inhibitor SGLT2 Diabetes

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Bayer · 2 shared drug classes
  2. SK Chemicals Co., Ltd. · 2 shared drug classes
  3. Ahn-Gook Pharmaceuticals Co.,Ltd · 2 shared drug classes
  4. AstraZeneca · 2 shared drug classes
  5. EMS · 2 shared drug classes
  6. Novartis · 2 shared drug classes
  7. Addpharma Inc. · 2 shared drug classes
  8. AceLink Therapeutics, Inc. · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Applied Biology, Inc.:

Cite this brief

Drug Landscape (2026). Applied Biology, Inc. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/applied-biology-inc. Accessed 2026-05-16.

Related